跳转至内容
Merck
所有图片(1)

文件

CDS023389

Sigma-Aldrich

达沙替尼

别名:

N-(2-氯-6-甲基苯基)-2-[[6-[4-(2-羟乙基)-1-哌嗪基]-2-甲基-4-嘧啶基]氨基]-5-噻唑甲酰胺

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C22H26ClN7O2S
CAS号:
302962-49-8
分子量:
488.01
MDL號碼:
MFCD11046566
分類程式碼代碼:
12352200
PubChem物質ID:
329796700

描述

AldrichCPR

形狀

solid

儲存溫度

-10 to -25°C

SMILES 字串

CC1=NC(NC2=NC=C(C(NC3=C(C=CC=C3Cl)C)=O)S2)=CC(N4CCN(CC4)CCO)=N1

InChI

1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)

InChI 密鑰

ZBNZXTGUTAYRHI-UHFFFAOYSA-N

基因資訊

human ... ABL1(25) , BLK(640) , EPHA2(1969) , FGR(2268) , FRK(2444) , FYN(2534) , HCK(3055) , KIT(3815) , LCK(3932) , LYN(4067) , PDGFRB(5159) , SRC(6714) , SRMS(6725) , YES1(7525)

正在寻找类似产品? 访问 产品对比指南

其他說明

请注意，Sigma-Aldrich 向早期发现研究人员提供该产品，作为独特化学品集合的一部分。Sigma-Aldrich 不收集本品的分析数据。买方负责确认产品标识和/或纯度。所有销售均为最终产品。

尽管 SIGMA-ALDRICH 中包含任何违反条款的条款和标准条款和条件以及 SIGMA-ALDRICH 与买方之间的协议，但 SIGMA-ALDRICH “按原样”销售本产品，且不对本产品做出任何声明或保证，包括任何 (A) 适销性保证；(B) 对某一特定用途的适合性的保证；(C) 防止侵犯第三方知识产权的保证；无论侵犯活动是由法律、交易过程、履行过程、贸易惯例还是其他原因引起的。

訊號詞

Danger

危險分類

Aquatic Chronic 1 - Carc. 2 - Eye Dam. 1 - Repr. 2 - Skin Irrit. 2 - STOT RE 1

標靶器官

Gastro-intestinal system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Kenta Mukaihara et al.
PloS one, 12(9), e0185321-e0185321 (2017-09-26)
Alveolar soft part sarcoma (ASPS) is an extremely rare metastatic soft tissue tumor with a poor prognosis for which no effective systemic therapies have yet been established. Therefore, the development of novel effective treatment approaches is required. Tyrosine kinases (TKs)
Maja Kim Kuepper et al.
Leukemia, 33(8), 1964-1977 (2019-03-08)
Tyrosine kinase inhibitor (TKI) therapy effectively blocks oncogenic Bcr-Abl signaling and induces molecular remission in the majority of CML patients. However, the disease-driving stem cell population is not fully targeted by TKI therapy in the majority of patients, and leukemic
Lei Liu et al.
Journal of pineal research, 67(2), e12588-e12588 (2019-05-30)
Chordoma is an extremely rare malignant bone tumor with a high rate of relapse. While cancer stem cells (CSCs) are closely associated with tumor recurrence, which depend on its capacity to self-renew and induce chemo-/radioresistance, whether and how CSCs participate
Diahann T S L Jansen et al.
Frontiers in immunology, 9, 8-8 (2018-02-07)
With the advent of novel strategies to induce tolerance in autoimmune and autoimmune-like conditions, clinical trials of antigen-specific tolerizing immunotherapy have become a reality. Besides safety, it will be essential to gather mechanistic data on responding CD4
Elpetra P M Timmermans-Sprang et al.
Veterinary and comparative oncology, 17(3), 413-426 (2019-05-10)
Human epidermal growth factor 2 (HER2) overexpression leads to aggressive mammary tumour growth. Although the prognosis of HER2+ tumours in humans is greatly improved using biologicals, therapy resistance, which may be caused by increased phosphatidyl-3-kinase (PI3K), rous sarcoma proto-oncogene (cSRC)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门